ROCHESTER, N.Y., Aug. 22, 2012 /PRNewswire/ -- Caliber Imaging & Diagnostics, formerly Lucid, Inc. (OTC Bulletin Board: LCDX), the leader in Rapid Cell Imaging and Diagnostics technology, today announced the release of two next-generation products in its FDA-cleared VivaScope® family. The new VivaScope 1500 and VivaScope 3000 produce high-quality images of living cells at the point of care. VivaScope imagers enable physicians to perform painless "optical" biopsies to diagnose disease, by providing dynamic native views of the area of interest. In addition, VivaScope products can be used by research and development teams for claims validation as well as research into skin disease.
Both the VivaScope 1500 and 3000 have the advantage of Caliber ID's Rapid Cell Imaging and Diagnostics technology that shows cellular detail with a resolution comparable to standard histology. Changes in the new VivaScope products include the availability of a touch-screen monitor and a multi-touch software interface that enables physicians to navigate images quickly and with the same ease as popular touch screen devices. Additionally, the Company has introduced redesigned optics and electronics for enhanced image quality and improved speed of data acquisition.
"Our Rapid Cell Imaging and Diagnosis [Rapid Cell ID] technology enables physicians to perform fast, accurate and painless 'optical biopsies' of skin," notes William J. Fox, Chief Technology Officer and Vice President of Engineering. "We have moved imaging and diagnosis out of the lab and to the point and time of care. The data shows that, in many cases, the use of our technology can eliminate the need for an invasive procedure on healthy skin, reducing costs